Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study

CONCLUSION: Despite FDA approval of 7 next-generation gram-negative antibiotics between 2014 and 2019, clinicians still frequently treat resistant gram-negative infections with older, generic antibiotics with suboptimal safety-efficacy profiles. Future antibiotics with innovative mechanisms targeting untapped pathogen niches, widely available susceptibility testing, and evidence demonstrating improved outcomes in resistant infections might enhance utilization.PRIMARY FUNDING SOURCE: U.S. Food and Drug Administration; NIH Intramural Research Program.PMID:38639548 | DOI:10.7326/M23-2309

Source: Annals of Internal Medicine - April 19, 2024 Category: Internal Medicine Authors: Jeffrey R Strich Ahmed Mishuk Guoqing Diao Alexander Lawandi Willy Li Cumhur Y Demirkale Ahmed Babiker Alex Mancera Bruce J Swihart Morgan Walker Christina Yek Maniraj Neupane Nathaniel De Jonge Sarah Warner Sameer S Kadri National Institutes of Health An Source Type: research